Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease

NCT02321280 is registered in ClinicalTrials.gov with University of Manitoba as lead sponsor.

NCT NCT02321280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02321280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease
Lead sponsor
University of Manitoba
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2015
Completion date
April 20, 2018
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease